<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02477215</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00024991</org_study_id>
    <nct_id>NCT02477215</nct_id>
  </id_info>
  <brief_title>Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma</brief_title>
  <official_title>Phase I/II Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Parameswaran Hari</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase I/II study is designed to first identify doses of MLN9708 and bendamustine that
      are associated with an acceptable adverse event profile when delivered together in 28-day
      cycles. Additionally, the study aims to assess the efficacy of the combination in patients
      with relapsed/refractory multiple myeloma. Responders (stable disease or more), will continue
      to receive up to eight cycles total in the absence of further progressive disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OVERVIEW: This Phase I/II study is designed to first identify doses of MLN9708 and
      bendamustine that are associated with an acceptable adverse event profile when delivered
      together in 28-day cycles. Additionally, the study aims to assess the efficacy of the
      combination in patients with relapsed/refractory multiple myeloma. Responders (stable disease
      or more),will continue to receive up to eight cycles total in the absence of further
      progressive disease.

      OVERVIEW OF THE DOSE ESCALATION/DE-ESCALATION: This study aims to assess the combination's
      efficacy in patients with relapsed/refractory multiple myeloma. Responders (stable disease or
      more) will continue to receive up to eight cycles total in the absence of further progressive
      disease. The dose of MLN9708 will be fixed at 4 mg given on days 1, 8 and 15. Dexamethasone
      will be administered at 40 mg (oral) on Days 1, 8, 15 of each 28 day cycle. Dexamethasone
      administered as 40 mg oral on Days 1, 8, 15 of each 28 day cycle. Three doses of bendamustine
      will be evaluated (Dose 1: 70 mg/m^2, days 1 and 2; Dose 2: 80 mg/m^2. days 1 and 2; and Dose
      3: 90 mg/m^2, days 1 and 2).

      PHASE 1 DESIGN: A 3+3 design was employed. At each dose, three patients were initially
      evaluated. When no dose limiting toxicities were observed, the bendamustine dose will be
      increased.

      PHASE 2 DESIGN: Design for Phase II portion of study: The MTD or a recommended phase 2 dose
      (RP2D) for the combination. The plan is to treat additional patients at that dose to assess
      efficacy and response to treatment. The investigators plan to enroll 19 patients (including
      those treated at the MTD in Phase I).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 9, 2015</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Actual">May 2, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose of Bendamustine</measure>
    <time_frame>Six months for each dosing cohort</time_frame>
    <description>Maximum tolerated dose of bendamustine in combination with fixed doses of ixazomib (MLN9708) and dexamethasone will be determined from the incidence of dose limiting toxicities at each dosage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>18 months</time_frame>
    <description>Objective response rate was defined as the number of subjects achieving a complete response (CR) or partial response (PR) after at least four cycles of ixazomib (MLN9708) and bendamustine plus dexamethasone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>36 months</time_frame>
    <description>Overall survival was determined as the average number of months subjects survived following enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>18 months</time_frame>
    <description>This measure is the number of months participants remain free from evidence of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Response Rates in Patients After Eight Cycles.</measure>
    <time_frame>18 months</time_frame>
    <description>Percentage of subject response rates at any point during the eight cycles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>36 months</time_frame>
    <description>Median time in months participants maintain CR, PR or stable disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Dose-Limiting Toxicity (DLT)</measure>
    <time_frame>Six months</time_frame>
    <description>A 3+3 design was employed. At each dose, three patients were initially evaluated. If no dose limiting toxicities were observed, the bendamustine dose was increased; if one dose limiting toxicity is observed, three additional patients were treated at that dose. A dose at which 2 DLTs were observed in 3 or 6 patients were judged to be too toxic and the lower dose was defined as the maximally tolerated dose (MTD).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>MLN9708, Bendamustine and Dexamethasone Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ixazomib 4 mg, days 1, 8, 15.
Dexamethasone 40 mg oral weekly.
Bendamustine dose levels: 70 mg/m^2, 80mg/m^2, or 90 mg/m^2 given on days 1 and 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MLN9708, Bendamustine and Dexamethasone MTD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ixazomib 4 mg, days 1, 8, 15.
Dexamethasone 40 mg oral weekly.
Bendamustine dose levels: MTD given on days 1 and 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLN9708</intervention_name>
    <description>4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.</description>
    <arm_group_label>MLN9708, Bendamustine and Dexamethasone Dose Escalation</arm_group_label>
    <arm_group_label>MLN9708, Bendamustine and Dexamethasone MTD</arm_group_label>
    <other_name>Ixazomib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>40 mg oral on Days 1, 8, 15 of each 28 day cycle.</description>
    <arm_group_label>MLN9708, Bendamustine and Dexamethasone Dose Escalation</arm_group_label>
    <arm_group_label>MLN9708, Bendamustine and Dexamethasone MTD</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine (multiple dose levels)</intervention_name>
    <description>70 mg/m^2, 80 mg/m^2, or 90 mg/m^2 on days 1 and 2</description>
    <arm_group_label>MLN9708, Bendamustine and Dexamethasone Dose Escalation</arm_group_label>
    <other_name>Treanda</other_name>
    <other_name>Treakisym</other_name>
    <other_name>Ribomustin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine (MTD)</intervention_name>
    <description>80 mg/m^2 on days 1 and 2</description>
    <arm_group_label>MLN9708, Bendamustine and Dexamethasone MTD</arm_group_label>
    <other_name>Treanda</other_name>
    <other_name>Treakisym</other_name>
    <other_name>Ribomustin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          1. Male or female patients 18 years or older.

          2. Voluntary written consent must be given before performance of any study related
             procedure not part of standard medical care, with the understanding that consent may
             be withdrawn by the patient at any time without prejudice to future medical care.

          3. Female patients who:

               -  Are postmenopausal for at least one year before the screening visit, OR

               -  Are surgically sterile, OR

               -  If they are of childbearing potential, agree to practice two effective methods of
                  contraception, at the same time, from the time of signing the informed consent
                  form through 90 days after the last dose of study drug, OR • Agree to practice
                  true abstinence when this is in line with the preferred and usual lifestyle of
                  the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal,
                  post-ovulation methods] and withdrawal are not acceptable methods of
                  contraception.)

             Male patients, even if surgically sterilized (ie, status post-vasectomy), must agree
             to one of the following:

               -  Agree to practice effective barrier contraception during the entire study
                  treatment period and through 90 days after the last dose of study drug, OR

               -  Agree to practice true abstinence when this is in line with the preferred and
                  usual lifestyle of the subject. (Periodic abstinence (eg, calendar, ovulation,
                  symptothermal, postovulation methods] and withdrawal are not acceptable methods
                  of contraception.)

          4. Patients must have have histologically or cytologically confirmed symptomatic Multiple
             Myeloma, who are non-responsive to or ineligible for autologous stem cell transplant,
             and who progress after prior exposure to proteasome inhibitor (bortezomib,
             carfilzomib) and lenalidomide or pomalidomide or thalidomide (IMID); and
             refractory/progressing to at least one of these agents and must meet at least one of
             the following parameters of measurable disease:

               -  Measurable levels of monoclonal protein (M protein): &gt; 1 g/dL of immunoglobin G
                  (IgG) or immunoglobin M (IgM) M-protein or &gt; 0.5 g/dL immunoglobin A (IgA) or
                  immunoglobin D (IgD) M protein on serum protein electrophoresis OR &gt; 200 mg/24h
                  of free light chain proteinuria on a 24 hour urine protein electrophoresis which
                  must be obtained within 4 weeks prior to registration OR &gt; 10 mg/dL involved free
                  light chain on serum free light chain testing with an abnormal kappa:lambda light
                  chain ratio.

               -  Patients with lytic bone disease, defined as at least one lytic lesion that can
                  be accurately measured in at least one dimension.

          5. Eastern Cooperative Oncology Group (ECOG) performance status and/or other performance
             status 0, 1, or 2.

          6. Patients are eligible after autologous or allogeneic stem cell transplantation.
             Allogeneic transplantation can be enrolled only if they have no ongoing transplant
             related side effects.

          7. Patients must be at least 2 weeks from major surgery, radiation therapy, participation
             in other investigational trials and have recovered from clinically significant
             toxicities of these prior treatments

          8. Patients must meet the following clinical laboratory criteria:

               -  Absolute neutrophil count (ANC) ≥ 1,000/mm3 and platelet count ≥ 75,000/mm3.
                  Platelet transfusions or granulocyte-colony stimulating factor (G-CSF) can be
                  used to help patients meet eligibility criteria but are not allowed within 3 days
                  before study enrollment.

               -  Total bilirubin &lt; 1.5 x the upper limit of the normal range (ULN), , OR, direct
                  bilirubin within normal limits (WNL), when total bilirubin is &gt;&gt;&lt; 1.5 x the ULN.

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &lt; 3 x ULN.

               -  Calculated creatinine clearance ≥ 30 mL/min.

        EXCLUSION CRITERIA

        Patients meeting any of the following exclusion criteria are not to be enrolled in the
        study:

          1. Female patients who are lactating or have a positive serum pregnancy test during the
             screening period.

          2. Failure to have fully recovered (ie, ≤ Grade 1 toxicity) from the reversible effects
             of prior chemotherapy except for peripheral neuropathy, which is addressed in
             exclusion criteria no. #14.

          3. Major surgery within 14 days before enrollment.

          4. Radiotherapy within 14 days before enrollment. If the involved field is limited
             (single disease focus not involving pelvis and involving &lt;36 Gy radiation), 7 days
             will be considered a sufficient interval between treatment and administration of
             Ixazomib provided hematologic inclusion parameters are met.

          5. Central nervous system involvement.

          6. Infection requiring systemic antibiotic therapy or other serious infection within 14
             days before study enrollment.

          7. Evidence of current uncontrolled cardiovascular conditions, including uncontrolled
             hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure,
             unstable angina, or myocardial infarction within the past 6 months.

          8. Systemic treatment, within 14 days before the first dose of IXAZOMIB, with strong
             inhibitors of cytochrome P1A2 (CYP1A2) (fluvoxamine, enoxacin, ciprofloxacin), strong
             inhibitors of cytochrome P3A (CYP3A) (clarithromycin, telithromycin, itraconazole,
             voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers
             (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of
             Ginkgo biloba or St. John's wort.

          9. Ongoing or active systemic infection, active hepatitis B or C virus infection, or
             known human immunodeficiency virus (HIV) positive.

         10. Any serious medical or psychiatric illness that could, in the investigator's opinion,
             potentially interfere with the completion of treatment according to this protocol.

         11. Known allergy to any of the study medications, their analogues, or excipients in the
             various formulations of any agent.

         12. Known GI disease or GI procedure that could interfere with the oral absorption or
             tolerance of IXAZOMIB including difficulty swallowing.

         13. Diagnosed or treated for another malignancy where the expected survival is less than
             two years will be excluded. Patients with nonmelanoma skin cancer or carcinoma in situ
             of any type are not excluded if they have undergone complete resection.

         14. Patient has ≥ Grade 2 peripheral neuropathy, or Grade 2 with pain on clinical
             examination during the screening period.

         15. Participation in other clinical trials, including those with other investigational
             agents not included in this trial, within 30 days of the start of this trial and
             throughout the duration of this trial.

         16. Patients that have previously been treated with IXAZOMIB, or participated in a study
             with IXAZOMIB whether treated with IXAZOMIB or not.

         17. Patients with a history of severe chronic obstructive pulmonary disease requiring
             ongoing oxygen support or those with a resting oxygen saturation &lt;92% on room air
             irrespective of the cause.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Parameswaran Hari, MD, MRCP, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Froedtert Hospital and the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 12, 2015</study_first_submitted>
  <study_first_submitted_qc>June 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2015</study_first_posted>
  <results_first_submitted>August 14, 2019</results_first_submitted>
  <results_first_submitted_qc>January 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 27, 2020</results_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Parameswaran Hari</investigator_full_name>
    <investigator_title>Section Head, Hematological Malignancies Director, Adult Blood and Marrow Transplant Program</investigator_title>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Ixazomib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT02477215/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bendamustine (70 mg/m^2), MLN9708, Dexamethasone</title>
          <description>MLN9708 : 4 mg, days 1, 8, 15.
Dexamethasone: 40 mg oral weekly.
Bendamustine: 70 mg/m^2 days 1 and 2</description>
        </group>
        <group group_id="P2">
          <title>Bendamustine (80 mg/m^2), MLN9708, Dexamethasone</title>
          <description>MLN9708 : 4 mg, days 1, 8, 15.
Dexamethasone: 40 mg oral weekly.
Bendamustine: 80 mg/m^2 days 1 and 2</description>
        </group>
        <group group_id="P3">
          <title>Bendamustine (90 mg/m^2), MLN9708, Dexamethasone</title>
          <description>MLN9708 : 4 mg, days 1, 8, 15.
Dexamethasone: 40 mg oral weekly.
Bendamustine: 90 mg/m^2 days 1 and 2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Dose Escalation Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Fixed Dose Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">No subjects were started in this group as it was not the optimal dose.</participants>
                <participants group_id="P2" count="20">Subjects in Period 1 did not continue into Period 2. This is a new subject population.</participants>
                <participants group_id="P3" count="0">No subjects were started in this group as it was not the optimal dose.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dose Escalation Phase: Bendamustine (70 mg/m^2), MLN9708, Dex.</title>
          <description>MLN9708: 4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.
Dexamethasone: 40 mg oral on Days 1, 8, 15 of each 28 day cycle.
Bendamustine: 70 mg/m^2 days 1 and 2</description>
        </group>
        <group group_id="B2">
          <title>Dose Escalation Phase: Bendamustine (80 mg/m^2), MLN9708, Dex.</title>
          <description>MLN9708: 4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.
Dexamethasone: 40 mg oral on Days 1, 8, 15 of each 28 day cycle.
Bendamustine: 80 mg/m^2 days 1 and 2</description>
        </group>
        <group group_id="B3">
          <title>Dose Escalation Phase: Bendamustine (90 mg/m^2), MLN9708, Dex.</title>
          <description>MLN9708: 4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.
Dexamethasone: 40 mg oral on Days 1, 8, 15 of each 28 day cycle.
Bendamustine: 90 mg/m^2 days 1 and 2</description>
        </group>
        <group group_id="B4">
          <title>Fixed Dose Phase</title>
          <description>MLN9708: 4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.
Dexamethasone: 40 mg oral on Days 1, 8, 15 of each 28 day cycle.
Bendamustine: 80 mg/m^2 days 1 and 2</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="20"/>
            <count group_id="B5" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose of Bendamustine</title>
        <description>Maximum tolerated dose of bendamustine in combination with fixed doses of ixazomib (MLN9708) and dexamethasone will be determined from the incidence of dose limiting toxicities at each dosage.</description>
        <time_frame>Six months for each dosing cohort</time_frame>
        <population>All participants received at least ne dose of Bendamustine at either 70 mg/m^2, 80 mg^2 or 90 mg/m^2.</population>
        <group_list>
          <group group_id="O1">
            <title>MLN9708, Bendamustine and Dexamethasone</title>
            <description>MLN9708: 4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.
Dexamethasone: 40 mg oral on Days 1, 8, 15 of each 28 day cycle.
Bendamustine:70 mg/m^2, 80 mg/m^2, or 90 mg/m^2 on days 1 and 2</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose of Bendamustine</title>
          <description>Maximum tolerated dose of bendamustine in combination with fixed doses of ixazomib (MLN9708) and dexamethasone will be determined from the incidence of dose limiting toxicities at each dosage.</description>
          <population>All participants received at least ne dose of Bendamustine at either 70 mg/m^2, 80 mg^2 or 90 mg/m^2.</population>
          <units>mg/m^2</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate</title>
        <description>Objective response rate was defined as the number of subjects achieving a complete response (CR) or partial response (PR) after at least four cycles of ixazomib (MLN9708) and bendamustine plus dexamethasone.</description>
        <time_frame>18 months</time_frame>
        <population>Subjects receiving the fixed dose of 80 mg/m^2 Bendamustine were included in this analysis. Results from five of the subjects in the Dose Escalation Phase of this study who also received 80 mg/m^2 Bendamustine were included in the analysis. One of the Dose Expansion Phase subjects did not complete sufficient dosing cycles for inclusion.</population>
        <group_list>
          <group group_id="O1">
            <title>MLN9708, Bendamustine and Dexamethasone</title>
            <description>Ixazomib 4 mg, days 1, 8, 15.
Dexamethasone 40 mg oral weekly.
Bendamustine dose levels: 80mg/m2 days 1,2
MLN9708: 4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.
Dexamethasone: 40 mg oral on Days 1, 8, 15 of each 28 day cycle.
Bendamustine: 80mg/m2 days 1,2</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate</title>
          <description>Objective response rate was defined as the number of subjects achieving a complete response (CR) or partial response (PR) after at least four cycles of ixazomib (MLN9708) and bendamustine plus dexamethasone.</description>
          <population>Subjects receiving the fixed dose of 80 mg/m^2 Bendamustine were included in this analysis. Results from five of the subjects in the Dose Escalation Phase of this study who also received 80 mg/m^2 Bendamustine were included in the analysis. One of the Dose Expansion Phase subjects did not complete sufficient dosing cycles for inclusion.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall survival was determined as the average number of months subjects survived following enrollment.</description>
        <time_frame>36 months</time_frame>
        <population>Subjects receiving the fixed dose of 80 mg/m^2 Bendamustine were included in this analysis. Results from five of the subjects in the Dose Escalation Phase of this study who also received 80 mg/m^2 Bendamustine were included in the analysis. One of the Dose Expansion Phase subjects did not complete sufficient dosing cycles for inclusion.</population>
        <group_list>
          <group group_id="O1">
            <title>MLN9708, Bendamustine and Dexamethasone</title>
            <description>MLN9708: 4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.
Dexamethasone: 40 mg oral on Days 1, 8, 15 of each 28 day cycle.
Bendamustine: 80 mg/m^2 days 1,2</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall survival was determined as the average number of months subjects survived following enrollment.</description>
          <population>Subjects receiving the fixed dose of 80 mg/m^2 Bendamustine were included in this analysis. Results from five of the subjects in the Dose Escalation Phase of this study who also received 80 mg/m^2 Bendamustine were included in the analysis. One of the Dose Expansion Phase subjects did not complete sufficient dosing cycles for inclusion.</population>
          <units>MONTHS</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" lower_limit="16.3" upper_limit="30.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>This measure is the number of months participants remain free from evidence of disease.</description>
        <time_frame>18 months</time_frame>
        <population>For this analysis, all 20 participants who received the fixed dose of 80 mg/m^2 Bendamustine and all 8 participants who received Bendamustine (80 mg/m^2) in the Dose Escalation phase, were combined.</population>
        <group_list>
          <group group_id="O1">
            <title>MLN9708, Bendamustine and Dexamethasone</title>
            <description>Ixazomib 4 mg, days 1, 8, 15.
Dexamethasone 40 mg oral weekly.
Bendamustine dose levels: 80mg/m2 days 1,2
MLN9708: 4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.
Dexamethasone: 40 mg oral on Days 1, 8, 15 of each 28 day cycle.
Bendamustine: 80mg/m2 days 1,2</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>This measure is the number of months participants remain free from evidence of disease.</description>
          <population>For this analysis, all 20 participants who received the fixed dose of 80 mg/m^2 Bendamustine and all 8 participants who received Bendamustine (80 mg/m^2) in the Dose Escalation phase, were combined.</population>
          <units>MONTHS</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" lower_limit="1.96" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Response Rates in Patients After Eight Cycles.</title>
        <description>Percentage of subject response rates at any point during the eight cycles.</description>
        <time_frame>18 months</time_frame>
        <population>Subjects receiving the fixed dose of 80 mg/m^2 Bendamustine were included in this analysis. Results from five of the subjects in the Dose Escalation Phase of this study who also received 80 mg/m^2 Bendamustine were included in the analysis. One of the Dose Expansion Phase subjects did not complete sufficient dosing cycles for inclusion.</population>
        <group_list>
          <group group_id="O1">
            <title>MLN9708, Bendamustine and Dexamethasone</title>
            <description>Ixazomib 4 mg, days 1, 8, 15.
Dexamethasone 40 mg oral weekly.
Bendamustine dose levels: 80mg/m2 days 1,2
MLN9708: 4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.
Dexamethasone: 40 mg oral on Days 1, 8, 15 of each 28 day cycle.
Bendamustine: 80mg/m2 days 1,2</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Response Rates in Patients After Eight Cycles.</title>
          <description>Percentage of subject response rates at any point during the eight cycles.</description>
          <population>Subjects receiving the fixed dose of 80 mg/m^2 Bendamustine were included in this analysis. Results from five of the subjects in the Dose Escalation Phase of this study who also received 80 mg/m^2 Bendamustine were included in the analysis. One of the Dose Expansion Phase subjects did not complete sufficient dosing cycles for inclusion.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DoR)</title>
        <description>Median time in months participants maintain CR, PR or stable disease.</description>
        <time_frame>36 months</time_frame>
        <population>Subjects receiving the fixed dose of 80 mg/m^2 Bendamustine were included in this analysis. Results from five of the subjects in the Dose Escalation Phase of this study who also received 80 mg/m^2 Bendamustine were included in the analysis. One of the Dose Expansion Phase subjects did not complete sufficient dosing cycles for inclusion.</population>
        <group_list>
          <group group_id="O1">
            <title>MLN9708, Bendamustine and Dexamethasone</title>
            <description>Ixazomib 4 mg, days 1, 8, 15.
Dexamethasone 40 mg oral weekly.
Bendamustine dose levels: 80mg/m2 days 1,2
MLN9708: 4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.
Dexamethasone: 40 mg oral on Days 1, 8, 15 of each 28 day cycle.
Bendamustine: 80mg/m2 days 1,2</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DoR)</title>
          <description>Median time in months participants maintain CR, PR or stable disease.</description>
          <population>Subjects receiving the fixed dose of 80 mg/m^2 Bendamustine were included in this analysis. Results from five of the subjects in the Dose Escalation Phase of this study who also received 80 mg/m^2 Bendamustine were included in the analysis. One of the Dose Expansion Phase subjects did not complete sufficient dosing cycles for inclusion.</population>
          <units>MONTHS</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="1" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Dose-Limiting Toxicity (DLT)</title>
        <description>A 3+3 design was employed. At each dose, three patients were initially evaluated. If no dose limiting toxicities were observed, the bendamustine dose was increased; if one dose limiting toxicity is observed, three additional patients were treated at that dose. A dose at which 2 DLTs were observed in 3 or 6 patients were judged to be too toxic and the lower dose was defined as the maximally tolerated dose (MTD).</description>
        <time_frame>Six months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bendamustine (70 mg/m^2), MLN9708, Dexamethasone</title>
            <description>MLN9708 : 4 mg, days 1, 8, 15.
Dexamethasone: 40 mg oral weekly.
Bendamustine: 70 mg/m^2 days 1 and 2</description>
          </group>
          <group group_id="O2">
            <title>Bendamustine (80 mg/m^2), MLN9708, Dexamethasone</title>
            <description>MLN9708 : 4 mg, days 1, 8, 15.
Dexamethasone: 40 mg oral weekly.
Bendamustine: 80 mg/m^2 days 1 and 2</description>
          </group>
          <group group_id="O3">
            <title>Bendamustine (90 mg/m^2), MLN9708, Dexamethasone</title>
            <description>MLN9708 : 4 mg, days 1, 8, 15.
Dexamethasone: 40 mg oral weekly.
Bendamustine: 90 mg/m^2 days 1 and 2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Dose-Limiting Toxicity (DLT)</title>
          <description>A 3+3 design was employed. At each dose, three patients were initially evaluated. If no dose limiting toxicities were observed, the bendamustine dose was increased; if one dose limiting toxicity is observed, three additional patients were treated at that dose. A dose at which 2 DLTs were observed in 3 or 6 patients were judged to be too toxic and the lower dose was defined as the maximally tolerated dose (MTD).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bendamustine (70 mg/m^2), MLN9708 and Dexamethasone</title>
          <description>MLN9708: 4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.
Dexamethasone: 40 mg oral on Days 1, 8, 15 of each 28 day cycle.
Bendamustine: 70 mg/m^2 on days 1 and 2</description>
        </group>
        <group group_id="E2">
          <title>Bendamustine (80 mg/m^2), MLN9708 and Dexamethasone</title>
          <description>MLN9708: 4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.
Dexamethasone: 40 mg oral on Days 1, 8, 15 of each 28 day cycle.
Bendamustine: 80 mg/m^2 on days 1 and 2.
This reporting group includes subjects from both the Dose Escalation and Fixed Dose Phases who received Bendamustine at 80 mg/m^2.</description>
        </group>
        <group group_id="E3">
          <title>Bendamustine (90 mg/m^2), MLN9708 and Dexamethasone</title>
          <description>MLN9708: 4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.
Dexamethasone: 40 mg oral on Days 1, 8, 15 of each 28 day cycle.
Bendamustine: 90 mg/m^2 on days 1 and 2</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE v4.03</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Mobitz type 1</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Fecal incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gastric hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Progressive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Exacerbated COPD</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Parameswaran Hari</name_or_title>
      <organization>Medical College of Wisconsin</organization>
      <phone>414-805-4600</phone>
      <email>phari@mcw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

